| PHVS | PRESS-RELEASE | bullish | 8/10 | Pharvaris presented positive Phase 3 RAPIDe-3 and long-term CHAPTER-1 trial data for deucrictibant, an oral B2 receptor | Mar 2, 2026 |
| TCRT | PRESS-RELEASE | mixed | 6/10 | Alaunos Therapeutics released early non-GLP preclinical data from two diet-induced obesity (DIO) mouse studies showing t | Mar 2, 2026 |
| RPRX | PRESS-RELEASE | neutral | 5/10 | Royalty Pharma is providing $250 million in non-dilutive, royalty-backed financing to Zymeworks, securing 30% of global | Mar 2, 2026 |
| ZYME | PRESS-RELEASE | bullish | 7/10 | Zymeworks secured $250 million in non-dilutive financing from Royalty Pharma through a royalty-backed note, funded by 30 | Mar 2, 2026 |
| ZYME | PRESS-RELEASE | bullish | 8/10 | Zymeworks reported strong 2025 financial results with 39% revenue growth to $106.0 million and a 34% reduction in net lo | Mar 2, 2026 |
| BLTE | PRESS-RELEASE | bullish | 9/10 | Belite Bio reported preliminary 2025 financial results and provided a significant business update, including positive Ph | Mar 2, 2026 |
| RYTM | PRESS-RELEASE | bullish | 8/10 | Rhythm Pharmaceuticals announced additional positive 52-week data from its Phase 3 TRANSCEND trial showing a -18.8% plac | Mar 1, 2026 |
| CLDX | PRESS-RELEASE | bullish | 8/10 | Celldex Therapeutics presented positive Phase 2 open-label extension data for barzolvolimab in ColdU and SD, showing tha | Mar 1, 2026 |
| SEPN | PRESS-RELEASE | bullish | 8/10 | Septerna announced positive Phase 1 results for SEP-631, an oral MRGPRX2 negative allosteric modulator, showing robust, | Mar 1, 2026 |
| UPB | PRESS-RELEASE | bullish | 8/10 | Upstream Bio released additional Phase 2 VIBRANT trial data for verekitug in chronic rhinosinusitis with nasal polyps (C | Mar 1, 2026 |
| ALXO | PRESS-RELEASE | mixed | 6/10 | ALX Oncology reported Q4 and full-year 2025 financial results alongside clinical updates, highlighting biomarker validat | Feb 28, 2026 |
| CGON | PRESS-RELEASE | neutral | 5/10 | CG Oncology reported financial results for Q4 and full year 2025, highlighting a cash position of $742.2 million as of D | Feb 28, 2026 |
| LYB | PRESS-RELEASE | bearish | 7/10 | LyondellBasell announced a significant dividend cut from $1.37 to $0.69 per share, a reduction of nearly 50%, citing ong | Feb 26, 2026 |
